CBD for Anxiety: What the Research Actually Shows

Last updated 3 August 2026 · Originally published 18 July 2021

Anxiety is one of the main reasons people try CBD, and one of its better-studied uses outside epilepsy. That is worth saying plainly, because it is not true of most CBD claims.

It also comes with a catch that almost no label mentions. Most positive controlled studies have used single or daily doses of around 300 to 600 mg, with some open-label work titrating higher. A typical shop-bought oil gives you 10 to 25 mg in a serving. Whatever the research shows, it was not testing what is in most bottles.

At a glance

Anxiety is among the better-studied non-seizure uses of CBD — but the evidence remains limited and inconsistent, and depends heavily on the dose, formulation and type of anxiety studied.
Most positive controlled studies used 300–600 mg. Most retail servings are a fraction of that.
Taking more is not a fix: higher doses do not reliably work better.
Expectation can influence what people feel, and may help explain why anecdotes are often more enthusiastic than the trials.
Anxiety is the one use where we would think twice about full spectrum, because THC can make anxiety worse in susceptible people.
CBD is not a replacement for therapy or medication, both of which are far better established — and CBD is not risk-free at high doses.

Why it might work

One leading explanation involves serotonin, rather than the cannabinoid receptors most people associate with cannabis. In laboratory and animal work, CBD’s anxiety-related effects frequently involve a serotonin receptor called 5-HT1A — though CBD acts on several molecular targets, and its mechanism in people has not been settled.^[9] SSRIs also work on serotonin, but mainly by blocking its reuptake rather than acting on that receptor directly.

That gives researchers a plausible pharmacological mechanism to investigate, rather than merely a marketing claim. Brain imaging studies back it up indirectly: when people are given CBD, activity changes in the regions involved in processing fear and emotion, in a pattern loosely resembling what established anxiety treatments do.^[1] Suggestive, not conclusive — a change on a scan is not the same as feeling better.

What the studies found

The famous ones are small and short. In 2010, Brazilian researchers gave people with social anxiety a single 400 mg dose and found their anxiety dropped significantly compared with placebo.^[2] The same group followed up in 2011, giving 600 mg before a simulated public speaking test, and again found less anxiety and discomfort than placebo.^[3]

Those results are genuine. But they describe one dose, one stressful afternoon, in a laboratory. Living with an anxiety disorder is a different problem, and far fewer studies have looked at it.

The largest dedicated trial arrived in 2024. Researchers in India gave 178 adults with mild-to-moderate anxiety either a nanodispersible CBD solution at 300–600 mg daily or a placebo for 12 weeks, within a 15-week study, and reported substantial improvements on both patient- and clinician-rated anxiety scales.^[4] That is far more meaningful than a public-speaking experiment. The caveats matter, though: it tested a specialised nanodispersible formulation rather than an ordinary oil, most of the authors were employees or executives of the companies involved in developing it, and the result has not been independently replicated.

Results elsewhere have been less encouraging. A 2022 trial found that 300 mg of CBD before exposure therapy sessions did not improve outcomes for people with treatment-resistant social anxiety or panic disorder with agoraphobia.^[10] That is the pattern across this literature: some studies find something, others find nothing.

Pull all the trials together and the picture gets murkier. A 2024 review looked at every randomised trial of CBD for diagnosed anxiety disorders from 2013 to 2023 — eleven of them — and found the results were often contradictory, with wildly different doses and different conditions studied.^[5] A meta-analysis the same year reported a large effect, but from eight studies and 316 people in total.^[11]

So: promising and under-evidenced at once. Both halves are true, and most articles pick one.

The dose problem

This is the gap between the research and the shop shelf, and it matters more than anything else here.

Many of the best-known positive experiments used 300 to 600 mg — though not every trial at those doses succeeded. A standard oil offers maybe 10 to 25 mg a serving. Getting to a trial-level dose from an ordinary bottle would mean going through it at a rate no manufacturer suggests and most people could not afford.

Nor is the answer simply to take more. Some experiments suggest a bell-shaped dose response, where an intermediate dose does more than a higher one, though that has not been shown consistently enough to identify an optimal dose. And the higher you go, the more likely CBD is to interact with other medication — and the more the safety questions matter.

Why the anecdotes are so much better than the evidence

Ask people who use CBD for anxiety and you will hear something very different from what the trials say. In a Project CBD survey, 1,631 people reported using CBD for mood disorders, and 92% reported at least some improvement in feelings of nervousness.^[6] That sounds emphatic — but it was self-selected and uncontrolled, with products, doses, diagnoses and THC exposure all varying.

Part of the explanation is uncomfortable. A 2021 experiment tested what happens when people are simply told an oil contains CBD. There was no consistent overall reduction in anxiety from the expectation alone — but people who already strongly believed CBD works reported less anxiety when they thought they had received it, and expectation altered some physiological measures too.^[7]

Belief does not explain everything. It measurably influences the response, in a field where most customers arrive already persuaded.

What CBD is being compared with

Anxiety disorders are common, and they are among the most treatable conditions in medicine. That is the context.

Therapy. CBT is one of the best-supported treatments for anxiety disorders, and the skills can outlast the treatment itself. It takes time, can be expensive, and exposure work can be uncomfortable while you are doing it.

Antidepressants are the usual first-line medication and work well for many people, though they take weeks and bring their own side effects.

Benzodiazepines like diazepam work fast, which is why they are still prescribed short-term. They are not for long-term use — tolerance and dependence build, and reducing or stopping them can produce withdrawal and rebound anxiety.

Against that, CBD’s position is modest. Therapy and established medication have been tested in far larger numbers of people over far longer periods, and their benefits and limits are much better understood. CBD may yet prove useful; its evidence base is not comparable.

It is also worth resisting the assumption that CBD is simply gentler. At higher doses it can cause sleepiness, digestive effects, medication interactions and raised liver enzymes. In an FDA-funded 2025 trial, about 5.6% of healthy adults taking 5 mg/kg daily developed substantial liver-enzyme elevations, compared with none on placebo.^[12] The elevations resolved after treatment stopped and nobody developed symptoms, but CBD’s long-term safety at anxiety-treatment doses remains uncertain.

If you are going to try it

Don’t stop anything you have been prescribed. And if anxiety is getting in the way of your life, the conversation to have is with a doctor, not a shop assistant.

Check for interactions. CBD affects how the body handles some medicines, and vice versa. That matters especially alongside psychiatric medication — combining it with an SSRI or a benzodiazepine is a question for a pharmacist.

Consider avoiding THC. We usually think full-spectrum products are a sensible starting point. Anxiety is the exception worth flagging: THC can be anxiety-provoking, particularly at higher doses and in susceptible people.^[8] Anyone who knows they are sensitive to it, or who simply wants that variable gone, may prefer a verified broad-spectrum product or an isolate. That is a precaution rather than evidence that those formulations treat anxiety better — and “THC-free” labelling is not always accurate, so check the lab report. Our guide to full spectrum, broad spectrum and isolate explains the differences.

Be realistic about what you are taking. A 10 mg serving is not what the studies used, and the research cannot really be cited in its favour.

None of this is medical advice. If anxiety is affecting your daily life, speak to a doctor — and if you are in crisis, contact your local emergency or mental health service rather than waiting.

For the wider picture, see our guide to CBD and what the research actually shows, or browse more in Mental Health.

References

Batalla A, Bos J, Postma A, Bossong MG. The impact of cannabidiol on human brain function: a systematic review. Frontiers in Pharmacology. 2021;11:618184. doi:10.3389/fphar.2020.618184
Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology. 2011;25(1):121–130. doi:10.1177/0269881110379283
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. doi:10.1038/npp.2011.6
Gundugurti PR, Banda N, Yadlapalli SSR, et al. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: a double blind multicenter randomized clinical trial. Asian Journal of Psychiatry. 2024;97:104073. doi:10.1016/j.ajp.2024.104073
Coelho CF, Vieira RP, Araújo-Junior OS, et al. The impact of cannabidiol treatment on anxiety disorders: a systematic review of randomized controlled clinical trials. Life. 2024;14(11):1373. doi:10.3390/life14111373
Project CBD. Cultivating Wellness: CBD survey results, mood disorders. Survey of self-reported outcomes; not a controlled study.
Spinella TC, Stewart SH, Naugler J, Yakovenko I, Barrett SP. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology. 2021;238(7):1965–1977. PubMed
Sharpe L, Sinclair J, Kramer A, de Manincor M, Sarris J. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine. 2020;18(1):374. doi:10.1186/s12967-020-02518-2
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836. doi:10.1007/s13311-015-0387-1
Kwee CMB, Baas JMP, van der Flier FE, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. European Neuropsychopharmacology. 2022;59:58–67. doi:10.1016/j.euroneuro.2022.04.003
Han K, Wang JY, Wang PY, Peng YCH. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Research. 2024;339:116049. doi:10.1016/j.psychres.2024.116049
Florian J, Salcedo P, Burkhart K, et al. Cannabidiol and liver enzyme level elevations in healthy adults: a randomized clinical trial. JAMA Internal Medicine. 2025;185(9):1070–1078. doi:10.1001/jamainternmed.2025.2366

About this article

Substantially rewritten in August 2026, consolidating our earlier reporting on CBD and anxiety into a single guide. This update adds the systematic reviews published since, sets out the gap between research doses and retail servings, and covers the role of expectation. With earlier reporting by Lisa Rennie, Shawn Tucker and Sabina Pulone.